News

The American Journal of Managed Care1d
DLBCL Outcomes Vary Sharply for Patients 80 Years and Older
A majority of cases of diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma globally, are ...
Rolling Out10d
5 astonishing advances in lymphoma treatment success
Discover how innovative lymphoma treatments are transforming patient outcomes, from targeted therapies to immunotherapy ...
Genomic analysis provides insight into underpinnings of new treatment combination for deadly, Asian-prevalent lymphoma
A multinational research team of clinicians and scientists from South Korea and Singapore has published positive findings ...
The Manila Times4d
European Commission approves Roche's Columvi as the first bispecific antibody for diffuse large B-cell lymphoma after initial therapy
Approval based on Phase III STARGLO study where Columvi in combination with chemotherapy showed a 41% reduction in the risk ...
Pharmabiz3d
Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy
Roche’s bispecific antibody, Columvi receives European approval for diffuse large B-cell lymphoma after initial therapy: Basel Tuesday, April 15, 2025, 10:00 Hrs [IST] Roche ann ...